Duke-Margolis Institute for Health Policy

We are excited to officially announce that Duke has elevated Duke-Margolis to a University Health Policy Institute! With this new recognition, Duke-Margolis will continue to address timely health policy challenges; amplify Duke’s collective ability to support research and education that impacts health policy locally, nationally, and across the globe; and deepen Duke’s recruitment and retention of dynamic faculty and scholars who will lead, research, and explore the most pressing health care challenges of the future. Read the press release here: https://duke.is/z/aqgs

Check out our latest white paper! Duke-Margolis researchers examine the use of real-world data and real-world evidence in accelerated approvals and coverage decisions for medical products, and offer policy considerations. In particular, the authors explore real-world endpoint selection, generalizability of evidence, approaches for registries and data repositories, point-of-care trials, external control arms, and private payer considerations in the context of leveraging RWD sources. Read more here: https://duke.is/9/6kkh

Only a few weeks until our next event! Explore opportunities and strategies to improve regulatory assessment of Biologic Licensing Applications during our event coming up on August 20. Participants will also have the opportunity to share comments during a moderated panel discussion. Visit our event webpage to read the draft agenda and register: https://duke.is/b/sdcu

📣THURSDAY: Join us for our upcoming event! We will gather experts to discuss recent developments and future applications of real-world evidence and real-world data policy. The draft agenda has been updated and now includes a speaker lineup. We look forward to hearing insights from these speakers: Stella Chang, OMNY Health Laura DiAngelo, AgencyIQ Hussein Ezzeldin, U.S. Food and Drug Administration Lee Fleisher, Rubrum Advising Richard Forshee, U.S. Food and Drug Administration Joe Franklin, Verily Life Sciences Inmaculada Hernandez, University of California San Diego Nicholaas Honig, Aetion, Inc. Dena Jaffe, Oracle Health Annette James, American Academy of Actuaries Rodrigo Refoios Camejo, GSK David Rhew, Microsoft Katy Sadowski, Boehringer Ingelheim Jaime Smith, Parexel Joanne Walker, The Evidence Base Learn more and register here: https://duke.is/w/ahyn

Many consider the Healthy Opportunities Pilots to be the nation's most expansive Medicaid program to address health-related social needs related to food, housing, transportation, interpersonal safety, and toxic stress. Join us on Thursday, August 29, to learn more about the lessons learned during the first two years of implementation as well as the future of the program: https://duke.is/8/e6sm

Next week, Duke-Margolis will convene with our Real-World Evidence Collaborative to review recent activities, discuss policy developments, and explore promising future applications of real-world evidence and real-world data. Check out the agenda to learn more about speakers and topics of discussion, and register here: https://duke.is/w/ahyn

Do you want to help shape the future of health care through policy? Duke-Margolis is hiring! We are looking for a Policy Research Associate to join our team and manage research projects related to health care finance. If you are an experienced researcher with an interest in health policy and finance, learn more about the job and apply here: https://lnkd.in/eQWBkEG

We are excited to share our students’ great work at the Duke Summer Research Showcase on July 26! Stop by Trent Semans Great Hall between 10 a.m. – 12 p.m. ET to meet our students and learn more about their research this summer. This showcase is presented by the Duke Undergraduate Research Support Office and the Duke Office of Undergraduate Education, and features research from several programs across Duke. Learn more: https://duke.is/4/yy3a

The meeting summary from our March 2024 event, "Enhancing Adoption of Innovative Clinical Trial Approaches," is now available! Read more below:

How has the Orphan Drug Act (ODA) impacted drug development in the past forty years? Core Faculty member Arti Rai has co-authored a Perspective article in the New England Journal of Medicine to discuss the ODA and explore the potential for further progress. Read more here: https://lnkd.in/eyeDM5Dn